市場調查報告書
商品編碼
1499414
膠原蛋白疾病血管疾病市場:按產品、適應症和最終用途 - 全球預測 2024-2030Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2024-2030 |
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
膠原病血管疾病市場規模預計2023年為298.3億美元,2024年達322.1億美元,預計2030年將達535.1億美元,複合年成長率為8.70%。
膠原血管疾病是一組涉及支持器官和身體其他部位的富含蛋白質的組織的疾病。這種結締組織對於皮膚、肌腱、骨骼、軟骨和血管的強度、彈性和結構至關重要。膠原病血管疾病可能是遺傳性的,也可能是由過度活躍的免疫系統引起的,導致身體攻擊自身組織的自體免疫疾病。這些疾病通常具有通用特徵,包括導致受影響器官和組織受損和功能障礙的發炎。此類別包括多種疾病,包括類風濕性關節炎、硬皮症、全身性紅斑性狼瘡、多發性肌炎、皮肌炎和全身性硬化症。膠原病血管疾病市場涵蓋醫療解決方案的需求和供應,例如針對影響結締組織的疾病的診斷、治療、療法和服務。該市場的應用包括臨床診斷、治療和持續的患者管理。最終使用者通常是醫療機構,例如醫院、診所、風濕病中心和居家照護機構。該市場也為研究和學術機構以及參與開發新治療方法的製藥和生物技術公司提供服務。影響膠原血管疾病市場需求的關鍵因素是:人們對膠原血管疾病的認知和理解不斷提高、全球自體免疫疾病盛行率上升、醫療保健基礎設施的改善以及醫療服務的可及性的改善。然而,他們面臨挑戰,例如與先進治療和藥物相關的高成本,以及嚴格的政府法規和核准流程。同時,膠原血管疾病的需求帶來了一些快速成長的機會,包括基因治療和幹細胞治療的進步,以及遠端醫療、行動醫療應用和穿戴式裝置在患者管理中的採用。
主要市場統計 | |
---|---|
基準年[2023] | 298.3億美元 |
預測年份 [2024] | 322.1億美元 |
預測年份 [2030] | 535.1億美元 |
複合年成長率(%) | 8.70% |
區域洞察
美國因其完善的醫療基礎設施、患者意識以及自體免疫疾病的高盛行率而成為心血管疾病的重要市場。專注於技術創新的大型製藥企業的存在和政府的支持政策正在促進市場的擴張。在南美洲,隨著醫療保健的改善和人們對這種疾病的認知不斷提高,膠原蛋白血管疾病市場正在擴大。政府加強醫療保健服務和醫學研究國際合作的措施預計將進一步提振市場。歐盟對 KEYWORD 的需求的特徵是全民健保系統的可用性以及對研究和開發的重視。嚴格的藥品核准規定確保了高標準的醫療服務。該地區的消費者期待最先進的治療設施,並受到治療的功效和安全性的驅動。包括膠原血管疾病在內的自體免疫疾病在中東呈上升趨勢,發展中的醫療保健產業高度依賴國際指南和藥物。非洲治療膠原血管疾病的能力各不相同,許多地區這些疾病的盛行率很高,而且缺乏先進的治療方法。隨著向現代醫療保健體系的過渡,中國市場正在迅速擴張,政府和私營部門對醫療保健的投資不斷增加,全球藥品的取得也不斷改善,影響著客戶的需求。日本市場反映了醫療保健領域技術整合的高水平,消費者基礎傾向於創新和護理品質。
FPNV定位矩陣
FPNV 定位矩陣對於評估供應商在膠原病血管疾病市場的定位至關重要。此矩陣提供了對供應商的全面評估,並檢驗了與業務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果,供應商被分為代表其成功程度的四個像限:前沿(F)、探路者(P)、利基(N)和重要(V)。
市場佔有率分析
市場佔有率分析是一種綜合工具,可以對膠原血管疾病市場供應商的現狀進行深入而詳細的評估。透過仔細比較和分析供應商的貢獻,您可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外,該分析還提供了對該行業競爭力的寶貴見解,包括研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊,供應商可以做出更明智的決策並製定有效的策略,以在市場競爭中保持領先地位。
策略分析與建議
策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對他們目前在膠原病血管疾病市場中的地位進行全面評估,使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析,以確定核心優勢和需要改進的領域。
[184 Pages Report] The Collagen Vascular Diseases Market size was estimated at USD 29.83 billion in 2023 and expected to reach USD 32.21 billion in 2024, at a CAGR 8.70% to reach USD 53.51 billion by 2030.
Collagen vascular diseases comprise a group of disorders that involve the protein-rich tissue that supports organs and other parts of the body. This connective tissue is essential for the strength, elasticity, and structure of skin, tendons, bones, cartilage, and blood vessels. Collagen vascular diseases can be hereditary or caused by an overactive immune system, resulting in autoimmune conditions where the body attacks its own tissues. These diseases often share common features, including inflammation, which can damage and dysfunction of affected organs and tissues. The category encompasses a variety of conditions, including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, and systemic sclerosis, among others. The market for collagen vascular diseases encompasses the demand and supply of medical solutions, including diagnostics, treatments, therapeutics, and services targeted towards diseases that affect connective tissue. Applications for this market include clinical diagnostics, therapeutic treatments, and ongoing patient management. End-users are typically healthcare facilities like hospitals, clinics, specialized rheumatology centers, and home care settings. This market also serves research and academic institutions and pharmaceutical and biotechnology companies involved in the development of new treatments. The key factors influencing the need for the collagen vascular diseases market include growing awareness and understanding of collagen vascular diseases, rising incidence of autoimmune diseases globally, improved healthcare infrastructure, and increased accessibility to medical services. However, the market faces challenges, such as high costs associated with advanced treatments and medications and stringent government regulations and approval processes. On the other hand, the need for collagen vascular diseases presents several burgeoning opportunities, such as ongoing advancements in gene and stem cell therapies and the adoption of telemedicine, mobile health applications, and wearables for patient management.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 29.83 billion |
Estimated Year [2024] | USD 32.21 billion |
Forecast Year [2030] | USD 53.51 billion |
CAGR (%) | 8.70% |
Regional Insights
The United States represents a significant market for collagen vascular diseases (CVDs), driven by a well-established healthcare infrastructure, patient awareness, and a high incidence of autoimmune diseases. The presence of leading pharmaceutical companies focusing on innovation, coupled with supportive government policies, contributes to market expansion. In South America, the collagen vascular diseases market is expanding as healthcare access improves and the population becomes more aware of these diseases. Government initiatives to strengthen healthcare provision and international collaborations for medical research are expected to propel the market further. The EU's need for collagen vascular diseases is characterized by the availability of universal healthcare systems and a strong focus on research and development. Stringent regulations regarding drug approvals ensure a high standard of care. Consumers in this region expect state-of-the-art treatment facilities and are driven by the effectiveness and safety profiles of treatments. The Middle East is experiencing a rise in autoimmune disorders, including collagen vascular diseases, and due to a developing healthcare sector, there is a reliance on international guidelines and medications. Africa's capacity to manage collagen vascular diseases is varied, with a greater prevalence of these conditions and a scarcity of advanced treatments in many regions. China's market is rapidly expanding with a shift towards modern healthcare systems, and increased investment in healthcare by the government and private sector, paired with greater access to global pharmaceuticals, is influencing customer needs. Japan's market reflects a high degree of technological integration in healthcare, with a consumer base inclined towards innovation and treatment quality.
Market Insights
The market dynamics represent an ever-changing landscape of the Collagen Vascular Diseases Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Collagen Vascular Diseases Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Collagen Vascular Diseases Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
Quest Diagnostics and Scipher Medicine have forged a multi-year partnership to widen the scope of diagnostic capabilities for rheumatoid arthritis (RA) management, leveraging the pioneering PrismRA test. This molecular signature response classifier (MSRC) facilitates the prediction of responses to TNF inhibitor therapies, which is crucial for managing RA. Quest's service extension to include advanced RNA extraction and next-generation sequencing ensures a more efficient assessment of patient responses to TNF inhibitors. The partnership capitalizes on Quest's nationwide network for specimen collection and sophisticated logistics, thereby enhancing patient access to precision diagnostic solutions. [Published On: 2023-11-28]
FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA
Biogen has announced the FDA approval of Tofidence, the inaugural tocilizumab biosimilar authorized for use in the U.S., offering new treatment options for individuals with rheumatoid arthritis (RA) and certain juvenile arthritis conditions. This milestone promises increased healthcare savings and broader therapeutic access, according to the details provided by the manufacturer. Tofidence has been validated based on rigorous data analysis, including a phase 1 and phase 3 study, affirming its safety and efficacy as a biosimilar alternative to the reference drug Actemra. [Published On: 2023-10-02]
American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
The American College of Rheumatology (ACR) has introduced its innovative Rheumatoid Arthritis (RA) Measures Toolkit, a comprehensive resource designed to dramatically enhance the quality of RA patient care. Emphasizing the importance of regular monitoring and individualized therapy, the toolkit offers invaluable tools, including training guides, multilingual outcome measure copies, and workflow samples, to ensure precise and effective tracking of disease activity and patient functionality. [Published On: 2023-08-09]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Collagen Vascular Diseases Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.
Market Segmentation & Coverage